Study on New Insights in Remodeling of Endocrine Cardiomyopathies: ASsessmentt of Intramyocardial, Molecular and NeUroendocrine Parameters in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in AcroMegaly - Endocrine cardiomyophaty: Response to cyclic GMP PDE5 inhibitors in Acromegaly cardiomyopathy - Endocrine cardiomyophaty: Response to cyclic GMP PDE5 inhibitors in Acromegaly cardiomyopathy

MBERTO I - POLICLINICO DI ROMA0 个研究点目标入组 15 人开始时间: 2018年1月8日最近更新: 2018年1月22日

适应症

试验速览

暂无简介。

•age>18 yrs; patients (men and women) with previous diagnosis of Acromegaly, surgically and/or clinically treated according to current
•guidelines, with stable parameters of Acromegaly disease in the last 3 months, and with concomitant cardiac hypertrophy and/or diastolic
•dysfunction developed independently of Acromegaly care and detected by 2D echocardiography
•Are the trial subjects under 18? no
•Number of subjects for this age range: 1
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 12
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 3

•congenital or valvular cardiomyopathy, recent ischemic heart disease or revascularization after a myocardical infarction (MI), and
•contraindications to tadalafil 20 mg use (hypersensitivity to tadalafil, nitrates use, severe cardiovascular disorders (in the past 6 months) such as unstable angina or severe heart failure (NYHA II or III), or a stroke or myocardial infarction, heart rhythm problems, blood pressure <90/50 mmHg, severe hepatic or kidney impairment, and known hereditary degenerative retinal disorders such as retinitis pigmentosa, history of NAION)
•and to MRI examination
•- pregnant or lactating women

发起方

MBERTO I - POLICLINICO DI ROMA